Skip to content
What’s Next for China’s Biotech Boom? episode artwork

Oct 9, 2026 11 min

What’s Next for China’s Biotech Boom?

from Morning Brief Hosted by BFM Media

The Hang Seng Biotech Index has outperformed the broader market this year, fuelled by a wave of out-licensing deals with Western drugmakers, stronger R&D capabilities and attractive valuations. Eight years after the first biotech listing in Hong Kong, a growing number of these companies are turning profitable and moving from clinical-stage developers into commercial drugmakers. But profitability remains uneven across the sector, and a new round of Fed tightening could weigh on valuations. Herald van der Linde, Head of Equity Strategy for Asia Pacific at HSBC, discusses how to value the sector, which healthcare sub-sectors he prefers, and the key catalysts and risks ahead. Image Credit: Shutterstock

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

What’s Next for China’s Biotech Boom?

0:00 11:09

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Morning Brief?

This episode is 11 minutes long.

When was this Morning Brief episode published?

This episode was published on October 9, 2026.

Can I download this Morning Brief episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.